Thrivent Financial for Lutherans lowered its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 12.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 37,742 shares of the medical research company's stock after selling 5,435 shares during the period. Thrivent Financial for Lutherans' holdings in IQVIA were worth $7,417,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Avior Wealth Management LLC grew its stake in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after acquiring an additional 87 shares during the last quarter. Synergy Asset Management LLC bought a new stake in IQVIA during the 4th quarter valued at about $33,000. Versant Capital Management Inc raised its holdings in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after buying an additional 93 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of IQVIA during the fourth quarter valued at approximately $60,000. Finally, UMB Bank n.a. increased its position in shares of IQVIA by 72.8% during the fourth quarter. UMB Bank n.a. now owns 401 shares of the medical research company's stock valued at $79,000 after acquiring an additional 169 shares in the last quarter. Institutional investors own 89.62% of the company's stock.
IQVIA Stock Down 2.3 %
Shares of IQV traded down $4.24 during midday trading on Tuesday, reaching $181.87. 693,444 shares of the stock were exchanged, compared to its average volume of 1,239,209. The company has a market capitalization of $32.07 billion, a P/E ratio of 24.24, a PEG ratio of 1.99 and a beta of 1.50. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 52 week low of $179.28 and a 52 week high of $254.54. The company's 50 day moving average is $194.58 and its two-hundred day moving average is $207.73.
IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
Analysts Set New Price Targets
IQV has been the subject of a number of research analyst reports. William Blair reissued an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. Stephens began coverage on IQVIA in a research report on Friday, December 20th. They set an "overweight" rating and a $250.00 price objective for the company. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th. Stifel Nicolaus reduced their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Finally, Truist Financial reaffirmed a "buy" rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and a consensus target price of $249.05.
Check Out Our Latest Research Report on IQV
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
